Exploring Cell Type-Specific Efficacy of Plasma-Activated Medium (PAM) on Endometrial Cancer Using Patient-Specific 2-D and 3-D cell Culture Systems (2024)
IF 4.6 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Eva Becker;Christina B. Walter;Juliane Scheid;Sara Y. Brucker;André Koch;Martin Weiss
{"title":"Exploring Cell Type-Specific Efficacy of Plasma-Activated Medium (PAM) on Endometrial Cancer Using Patient-Specific 2-D and 3-D cell Culture Systems (2024)","authors":"Eva Becker;Christina B. Walter;Juliane Scheid;Sara Y. Brucker;André Koch;Martin Weiss","doi":"10.1109/TRPMS.2024.3421601","DOIUrl":null,"url":null,"abstract":"Endometrial cancer (EC) is the most common tumor of the female reproductive organs in industrialized nations and an increasingly frequent disease in premenopausal women, which necessitates the development of fertility-preserving alternative treatment modalities without radical hysterectomy. In this study, we progressively elucidate the cancer specific the impact of plasma activated media (PAM) on EC, transitioning from conventional single cell models to more clinically relevant patient-derived 3-D organoid systems of different tumor gradings compared to healthy endometrial tissue, emphasizing a novel experimental approach. Significantly, we demonstrate an increasing impact of PAM on patient-derived high-grade EC organoids accompanied with a dose-dependent rise in oxidative stress levels, contrasting with no alterations in healthy endometrial tissue. These findings collectively suggest that the application of plasma-activated liquid holds promise for expanding fertility-preserving therapies for endometrial carcinoma and contributing to future disease control. In conclusion, this research pioneers a patient-specific and stepwise investigation into the therapeutic potential of PAM on EC and contributes to the evolving landscape of personalized cancer therapies, offering promising avenues for future clinical applications.","PeriodicalId":46807,"journal":{"name":"IEEE Transactions on Radiation and Plasma Medical Sciences","volume":"9 2","pages":"259-268"},"PeriodicalIF":4.6000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ieeexplore.ieee.org/stamp/stamp.jsp?tp=&arnumber=10589343","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IEEE Transactions on Radiation and Plasma Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://ieeexplore.ieee.org/document/10589343/","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Endometrial cancer (EC) is the most common tumor of the female reproductive organs in industrialized nations and an increasingly frequent disease in premenopausal women, which necessitates the development of fertility-preserving alternative treatment modalities without radical hysterectomy. In this study, we progressively elucidate the cancer specific the impact of plasma activated media (PAM) on EC, transitioning from conventional single cell models to more clinically relevant patient-derived 3-D organoid systems of different tumor gradings compared to healthy endometrial tissue, emphasizing a novel experimental approach. Significantly, we demonstrate an increasing impact of PAM on patient-derived high-grade EC organoids accompanied with a dose-dependent rise in oxidative stress levels, contrasting with no alterations in healthy endometrial tissue. These findings collectively suggest that the application of plasma-activated liquid holds promise for expanding fertility-preserving therapies for endometrial carcinoma and contributing to future disease control. In conclusion, this research pioneers a patient-specific and stepwise investigation into the therapeutic potential of PAM on EC and contributes to the evolving landscape of personalized cancer therapies, offering promising avenues for future clinical applications.